We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.
AIDS Vaccines by the Numbers: Trials, discoveries, money and more
Access to the Dapivirine Vaginal Ring: A timeline on progress
CAB-LA Trials at a Glance
This infographic shares a breakdown of the current injectable CAB for PrEP trials including ongoing sub-studies.
Time to Develop a Vaccine
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.
Efficacy Study Design
This graphic details the trial design behind HPTN 083 and HPTN 084, two-large scale efficacy trials testing cabotegravir, an antiretroviral formulated as an injectable for long-lasting pre- exposure prophylaxis (PrEP).
To learn more, read An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP.
Access to the Dapivirine Vaginal Ring: A timeline on progress
This infographic shows the timeline of progress for end user access to Dapivirine Vaginal Ring.
PEPFAR-Funded PrEP and VMMC Services in 14 Priority Countries
This infographic shows that PEPFAR’s increased investment and creation of a budget code resulted in improved scale-up of VMMC (VMMC). A budget code could have the same impact if applied to PrEP initiations.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.